
Opinion|Videos|August 14, 2024
EMA vs Telomerase Inhibitor for RS+ patients after ESA failure
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series

- With the advent of new options for treatment after ESAs for patients with LR-MDS, please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the RS positive patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
2
Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL
3
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC
4
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
5





















